查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
生技藥品藥物研發市場 - 全球與區域分析（2023-2033）
市場調查報告書
商品編碼
1389594

生技藥品藥物研發市場 - 全球與區域分析（2023-2033）

Biologics Drug Discovery Market - A Global and Regional Analysis, 2023-2033
出版日期: | 出版商: BIS Research | 英文 155 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

生技藥品藥物研發代表了藥物研究和開發的革命性範例，它利用生物系統固有的複雜性來創建有針對性的治療性介入。

與傳統的小分子藥物不同，生物製藥是大而複雜的分子，例如蛋白質、抗體和核酸，通常源自活生物體。這種方法可以對疾病做出更精確和量身定做的反應，特別是在慢性病和自體免疫疾病領域。生技藥品藥物研發的過程包括闡明目標疾病的複雜生物學、識別關鍵生物分子和途徑，以及設計可以調節這些目標的療法。這種對生物複雜性的細緻入微的理解使得能夠開發出比傳統藥物具有更高特異性和功效的治療方法，並且通常副作用更少。

本報告考察了全球生技藥品藥物研發市場，並提供了市場概述，包括按方法、製造類型、地區分類的趨勢，和參與市場的公司概況。

目錄

第1章 市場：產業展望

  • 趨勢：當前和未來的影響評估
  • 供應鏈概覽
  • 研究發展回顧
  • 監管狀況
  • COVID-19 影響分析
  • 市場動態概覽

第2章 應用

  • 應用細分
  • 應用概述
  • 全球生物藥物研發市場（按方法）
    • 目標識別/檢驗
    • 命中生成/檢驗
    • 線索識別
    • 潛在客戶最佳化
  • 全球生物藥物研發市場（按製造類型）
    • 內部製造
    • 契約製造

第3章 產品

  • 產品細分
  • 產品概要
  • 全球生技藥品藥物研發市場（依類型）
    • 單株抗體
    • 重組蛋白
    • 其他

第4章 區域

  • 區域概況
  • 促進因素和抑制因素
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第5章 市場-競爭形勢與公司概況

  • 競爭形勢
  • 公司簡介
    • AbbVie, Inc.
    • Amgen, Inc.
    • Astellas Pharma, Inc.
    • AstraZeneca, Plc
    • Bayer AG
    • Bicon Ltd.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Eli Lily and Company
    • F.Hoffmann-La Roche AG
    • GenScript
    • Gilead Sciences, Inc.
    • GlaxoSmithKline, Plc
    • Johnson and Johnson
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk
    • Pfizer
    • Sanofi
    • Teva Pharmaceutical Industries, Ltd.
簡介目錄
Product Code: BHP0493SB

“Advancements in Biologics Drug Discovery Propel Market Growth.”

Biologics drug discovery represents a revolutionary paradigm in pharmaceutical research and development, leveraging the inherent complexities of biological systems to create targeted therapeutic interventions. Unlike traditional small-molecule drugs, biologics are large, complex molecules typically derived from living organisms, such as proteins, antibodies, or nucleic acids. This approach allows for a more precise and tailored response to diseases, particularly in the realm of chronic conditions and autoimmune disorders. The process of biologics drug discovery involves unraveling the intricate biology of the targeted disease, identifying key biomolecules or pathways, and designing therapeutic agents that can modulate these targets. This nuanced understanding of the biological intricacies enables the development of therapies that exhibit higher specificity, efficacy, and often fewer side effects compared to conventional drugs.

  • The report highlights the transformative impact of biologic therapies on individuals suffering from chronic inflammatory diseases, showcasing how these treatments have not only reduced dependency on health and welfare systems but also improved patients' physical function, enabling them to live more independently.
  • The report delves into various factors influencing the industry, including recent trends, technological advancements, and regulatory aspects. It outlines the market's segmentation based on product, method, manufacture, and geographical regions.
  • The report strategically segments the global biologics drug discovery market based on the phase of discovery, manufacturing type, and product type.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent companies in this market are:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca, Plc
  • Bayer AG
  • Bicon Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lily and Company
  • F.Hoffmann-La Roche AG
  • GenScript
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Plc
  • Johnson and Johnson
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries, Ltd.

Key Questions Answered:

  • What are the major market drivers, challenges, and opportunities in the global biologics drug discovery market and their case studies?
  • How the biologics drug discovery market evolve and what did is its scope in the future?
  • What is the market share of the leading segments and sub-segments of the global biologics drug discovery market in 2023 and 2033?
  • How will each segment of the global biologics drug discovery market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2033?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period between 2023 and 2033?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What will be the growth rate of the outsourced manufacturing segment during the forecast period?

Table of Contents

1. Markets: Industry Outlook

  • 1.1. Trends: Current and Future Impact Assessment
    • 1.1.1. Usage of AI/ML to Accelerate Drug Development
    • 1.1.2. Growing Emphasis on Developing Biosimilars and Biobetters
    • 1.1.3. Shift Towards Targeted and Precision Medicine
  • 1.2. Supply Chain Overview
    • 1.2.1. Value Chain Analysis
  • 1.3. R&D Review
    • 1.3.1. Patent Filing Trend by Country, by Company
  • 1.4. Regulatory Landscape
  • 1.5. Impact Analysis COVID-19
  • 1.6. Market Dynamics Overview
    • 1.6.1. Market Drivers
    • 1.6.2. Market Restraints
    • 1.6.3. Market Opportunities

2. Application

  • 2.1. Application Segmentation
  • 2.2. Application Summary
  • 2.3. Global Biological Drug Discovery Market (by Method)
    • 2.3.1. Target Identification/ validation
    • 2.3.2. Hit Generation/ Validation
    • 2.3.3. Lead Identification
    • 2.3.4. Lead Optimization
  • 2.4. Global Biological Drug Discovery Market (by Manufacture Type)
    • 2.4.1. In-House Manufacturing
    • 2.4.2. Outsourced Manufacturing

3. Product

  • 3.1. Product Segmentation
  • 3.2. Product Summary
  • 3.3. Global Biologics Drug Discovery Market (by Type)
    • 3.3.1. Monoclonal Antibodies
      • 3.3.1.1. Global Monoclonal Antibodies by Method
        • 3.3.1.1.1. Target Identification/ Validation
          • 3.3.1.1.1.1. Functional Genomics/Proteomics
          • 3.3.1.1.1.2. Cell-based Assay
          • 3.3.1.1.1.3. CRISPR/Knockout Studies/Cas9
          • 3.3.1.1.1.4. Animal/Disease Based Models
          • 3.3.1.1.1.5. Computational/in-Silico/Bioinformatics
        • 3.3.1.1.2. Hit Generation/ Validation
          • 3.3.1.1.2.1. mAb Sequencing
          • 3.3.1.1.2.2. Hybridoma Screening
          • 3.3.1.1.2.3. Customized Synthetic Library Screening
          • 3.3.1.1.2.4. Phase Display Screening
          • 3.3.1.1.2.5. High-Throughput Screening
          • 3.3.1.1.2.6. Others
        • 3.3.1.1.3. Lead Identification
          • 3.3.1.1.3.1. Phase Display
          • 3.3.1.1.3.2. ELISA/ADCC & CDC Assay
          • 3.3.1.1.3.3. Array-Based Screening
          • 3.3.1.1.3.4. Hybridoma Screening and Humanization
          • 3.3.1.1.3.5. Bioanalytical Analysis
          • 3.3.1.1.3.6. Others Assays
        • 3.3.1.1.4. Lead Optimization
          • 3.3.1.1.4.1. Humanization
          • 3.3.1.1.4.2. Affinity Analysis
          • 3.3.1.1.4.3. Protein Engineering
          • 3.3.1.1.4.4. In-Vitro/In-Vivo efficacy Assays
          • 3.3.1.1.4.5. Others
    • 3.3.2. Recombinant Proteins
      • 3.3.2.1. Global Protein Recombinant by Method
        • 3.3.2.1.1. Target Identification/ Validation
          • 3.3.2.1.1.1. Functional Genomics/Proteomics
          • 3.3.2.1.1.2. Cell-based Assay
          • 3.3.2.1.1.3. CRISPR/Knockout Studies/Cas9
          • 3.3.2.1.1.4. Animal/Disease Based Models
          • 3.3.2.1.1.5. Computational/in-Silico/Bioinformatics
        • 3.3.2.1.2. Hit Generation/ Validation
          • 3.3.2.1.2.1. mAb Sequencing
          • 3.3.2.1.2.2. Hybridoma Screening
          • 3.3.2.1.2.3. Customized Synthetic Library Screening
          • 3.3.2.1.2.4. Phase Display Screening
          • 3.3.2.1.2.5. High-Throughput Screening
          • 3.3.2.1.2.6. Others
        • 3.3.2.1.3. Lead Identification
          • 3.3.2.1.3.1. Phase Display
          • 3.3.2.1.3.2. ELISA/ADCC & CDC Assay
          • 3.3.2.1.3.3. Array-Based Screening
          • 3.3.2.1.3.4. Hybridoma Screening and Humanization
          • 3.3.2.1.3.5. Bioanalytical Analysis
          • 3.3.2.1.3.6. Others Assays
        • 3.3.2.1.4. Lead Optimization
          • 3.3.2.1.4.1. Humanization
          • 3.3.2.1.4.2. Affinity Analysis
          • 3.3.2.1.4.3. Protein Engineering
          • 3.3.2.1.4.4. In-Vitro/In-Vivo efficacy Assays
          • 3.3.2.1.4.5. Others
    • 3.3.3. Other Biologics

4. Region

  • 4.1. Regional Summary
    • Table: Biologics Drug Discovery Market, By Region, ($ Million), 2022-2033
  • 4.2. Drivers and Restraints
  • 4.3. North America
    • Key Market Participants in North America
    • Business Drivers
    • Business Challenges
    • 4.3.1. Application
      • Table: North America Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.3.2. Product
      • Table: North America Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.3.3. North America (by Country)
      • 4.2.4.1. U.S.
        • Table: U.S. Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.2.4.2. Canada
        • Table: Canada Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.3. Europe
    • 4.3.1. Key Market Participants in Europe
    • 4.3.2. Business Drivers
    • 4.3.3. Business Challenges
    • 4.3.4. Application
      • Table: Europe Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.3.3. Product
      • Table: Europe Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.3.4. Europe (by Country)
      • 4.3.4.1. France
        • Table: France Biologics Drug Discovery Market, By Manufacture Tyoe ($ Million), 2022-2033
      • 4.3.4.2. Germany
        • Table: Germany Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.3. U.K.
        • Table: U.K. Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.4. Switzerland
        • Table: Swizterland Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.3.4.5. Rest-of-Europe
        • Table: Rest-of Europe Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.4. Asia-Pacific
    • 4.4.1. Key Market Participants in Asia-Pacific
    • 4.4.2. Business Drivers
    • 4.4.3. Business Challenges
    • 4.4.2. Application
      • Table: Asia-Pacific Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.4.3. Product
      • Table: Asia-Pacific Biologics Drug Discovery Market, By Type ($ Million), 2022-2033
    • 4.4.4. Asia-Pacific (by Country)
      • 4.4.4.1. China
        • Table: China Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.2. India
        • Table: India Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.3. Japan
        • Table: Japan Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.4. Australia
        • Table: Australia Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
      • 4.4.4.5. Rest-of-Asia-Pacific
        • Table: Rest-of-Asia-Pacific Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
  • 4.5. Rest-of-the-World
    • 4.5.1. Key Market Participants in Rest-of-the-World
    • 4.5.2. Business Drivers
    • 4.5.3. Business Challenges
    • 4.5.4. Application
      • Table: Rest-of-the-World Biologics Drug Discovery Market, By Manufacture Type ($ Million), 2022-2033
    • 4.5.4. Product
      • Table: Rest-of-the-World Biologics Drug Discovery Market, By Type ($ Million), 2022-2033

5. Markets - Competitive Landscape & Company Profiles

  • 5.1. Competitive Landscape
  • 5.2. Company Profile
    • 5.2.1. AbbVie, Inc.
      • 5.2.1.1. Company Overview
      • 5.2.1.2. Product Portfolio
      • 5.2.1.3. Analyst View
    • 5.2.2. Amgen, Inc.
      • 5.2.2.1. Company Overview
      • 5.2.2.2. Product Portfolio
      • 5.2.2.3. Analyst View
    • 5.2.3. Astellas Pharma, Inc.
      • 5.2.3.1. Company Overview
      • 5.2.3.2. Product Portfolio
      • 5.2.3.3. Analyst View
    • 5.2.4. AstraZeneca, Plc
      • 5.2.4.1. Company Overview
      • 5.2.4.2. Product Portfolio
      • 5.2.4.3. Analyst View
    • 5.2.5. Bayer AG
      • 5.2.5.1. Company Overview
      • 5.2.5.2. Product Portfolio
      • 5.2.5.3. Analyst View
    • 5.2.6. Bicon Ltd.
      • 5.2.6.1. Company Overview
      • 5.2.6.2. Product Portfolio
      • 5.2.6.3. Analyst View
    • 5.2.7. Boehringer Ingelheim GmbH
      • 5.2.7.1. Company Overview
      • 5.2.7.2. Product Portfolio
      • 5.2.7.3. Analyst View
    • 5.2.8. Bristol-Myers Squibb Company
      • 5.2.8.1. Company Overview
      • 5.2.8.2. Product Portfolio
      • 5.2.8.3. Analyst View
    • 5.2.9. Eli Lily and Company
      • 5.2.9.1. Company Overview
      • 5.2.9.2. Product Portfolio
      • 5.2.9.3. Analyst View
    • 5.2.10. F.Hoffmann-La Roche AG
      • 5.2.10.1. Company Overview
      • 5.2.10.2. Product Portfolio
      • 5.2.10.3. Analyst View
    • 5.2.11. GenScript
      • 5.2.11.1. Company Overview
      • 5.2.11.2. Product Portfolio
      • 5.2.11.3. Analyst View
    • 5.2.12. Gilead Sciences, Inc.
      • 5.2.12.1. Company Overview
      • 5.2.12.2. Product Portfolio
      • 5.2.12.3. Analyst View
    • 5.2.13. GlaxoSmithKline, Plc
      • 5.2.13.1. Company Overview
      • 5.2.13.2. Product Potfolio
      • 5.2.13.3. Analyst View
    • 5.2.14. Johnson and Johnson
      • 5.2.14.1. Company Overview
      • 5.2.14.2. Product Potfolio
      • 5.2.14.4. Analyst View
    • 5.2.15. Laboratory Corporation of America Holdings
      • 5.2.15.1. Company Overview
      • 5.2.15.2. Product Potfolio
      • 5.2.15.3. Analyst View
    • 5.2.16. Merck KGaA
      • 5.2.16.1. Company Overview
      • 5.2.16.2. Product Potfolio
      • 5.2.16.4. Analyst View
    • 5.2.17. Novartis AG
      • 5.2.17.1. Company Overview
      • 5.2.17.2. Product Potfolio
      • 5.2.17.3. Analyst View
    • 5.2.18. Novo Nordisk
      • 5.2.18.1. Company Overview
      • 5.2.18.2. Product Potfolio
      • 5.2.18.3. Analyst View
    • 5.2.19. Pfizer
      • 5.2.19.1. Company Overview
      • 5.2.19.2. Product Potfolio
      • 5.2.19.3. Analyst View
    • 5.2.20. Sanofi
      • 5.2.20.1. Company Overview
      • 5.2.20.2. Product Potfolio
      • 5.2.20.3. Analyst View
    • 5.2.21. Teva Pharmaceutical Industries, Ltd.
      • 5.2.21.1. Company Overview
      • 5.2.21.2. Product Potfolio
      • 5.2.21.3. Analyst View